AIM: To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori(H. pylori) eradication in Chinese regions.METHODS: A systematic review and meta-analysis of randomized controlled ...AIM: To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori(H. pylori) eradication in Chinese regions.METHODS: A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for H. pylori eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the H. pylori eradication rate; the secondary outcome was the compliance with therapy. The Pub Med, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction.RESULTS: We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the H. pylori eradication rate was significantly higher for 7-d nonbismuth concomitant quadruple therapy than for 7-d triple therapy(91.2% vs 77.9%, risk ratio = 1.17, 95%CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups(86.9% vs 86.0%). However, higher compliance was achieved with concomitant therapy than with sequential therapy.CONCLUSION: The H. pylori eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.展开更多
目的观察新三联联用灭 Hp 胶囊对消化性溃疡疗效及溃疡愈合质量的影响.方法采用随机双盲对照研究,75例活动期消化性溃疡并 Hp阳性患者随机服用①新三联:兰索拉唑+克拉霉素+阿莫西林;②"灭 Hp 胶囊"四联:新三联,连用10 d+灭 Hp...目的观察新三联联用灭 Hp 胶囊对消化性溃疡疗效及溃疡愈合质量的影响.方法采用随机双盲对照研究,75例活动期消化性溃疡并 Hp阳性患者随机服用①新三联:兰索拉唑+克拉霉素+阿莫西林;②"灭 Hp 胶囊"四联:新三联,连用10 d+灭 Hp 胶囊,连用28d;③安慰剂:胃舒平,连用28 d.疗程结束后4 wk 复查内镜,观察 Hp 根治和溃疡愈合情况,并评价再生粘膜组织学成熟度.结果新三联和"灭 Hp 胶囊"四联组溃疡愈合率和 Hp 根治率分别为88%,92%和100%,96%,(P>0.05),但其再生粘膜成熟度后者(优占89%)优于前者(优占41%)(P<.05);两组均明显优于安慰剂组溃疡愈合率(20%,P<0.05),Hp 根治率(0.0%,均 P<0.01)和再生粘膜组织成熟度(以差者为主占67%,分别 P<0.05,P<0.01).结论灭 Hp 胶囊四联疗法不但获得理想的 Hp 根治率和溃疡愈合率,更有显著提高溃疡愈合质量作用;为中西医结合治疗消化性溃疡开辟了新途径.展开更多
目的:探讨和总结陆金根教授治疗炎症性肠病的学术思想和临床用药规律,探索名老中医经验整理的方法。方法:收集上海中医药大学附属龙华医院2011—2017门诊陆金根教授治疗炎症性肠病典型医案,对所选医案中符合纳入标准的药物运用Excel表...目的:探讨和总结陆金根教授治疗炎症性肠病的学术思想和临床用药规律,探索名老中医经验整理的方法。方法:收集上海中医药大学附属龙华医院2011—2017门诊陆金根教授治疗炎症性肠病典型医案,对所选医案中符合纳入标准的药物运用Excel表进行收录,然后用SPSS 21. 0 for windows统计软件进行聚类分析。结果:共有162份医案纳入研究,共计就诊622次,共得药物225味,出现的总频次为10411,常用中药有白术、败酱草、白芍、大血藤、山药等27味。聚类分析发现清热解毒药、化湿药、理气药、补虚药、收涩药和活血化瘀药等为陆金根教授治疗炎症性肠病的常用配伍药类。红藤败酱散、白头翁汤、痛泻要方、参苓白术散、甘麦大枣汤等为陆老治疗炎症性肠病的基本方药。结论:陆老治疗炎症性肠病体现出"以清为主,清补结合"的学术思想。聚类分析结果客观反映了陆金根教授临床用药规律。展开更多
文摘AIM: To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori(H. pylori) eradication in Chinese regions.METHODS: A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for H. pylori eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the H. pylori eradication rate; the secondary outcome was the compliance with therapy. The Pub Med, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction.RESULTS: We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the H. pylori eradication rate was significantly higher for 7-d nonbismuth concomitant quadruple therapy than for 7-d triple therapy(91.2% vs 77.9%, risk ratio = 1.17, 95%CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups(86.9% vs 86.0%). However, higher compliance was achieved with concomitant therapy than with sequential therapy.CONCLUSION: The H. pylori eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.
文摘目的观察新三联联用灭 Hp 胶囊对消化性溃疡疗效及溃疡愈合质量的影响.方法采用随机双盲对照研究,75例活动期消化性溃疡并 Hp阳性患者随机服用①新三联:兰索拉唑+克拉霉素+阿莫西林;②"灭 Hp 胶囊"四联:新三联,连用10 d+灭 Hp 胶囊,连用28d;③安慰剂:胃舒平,连用28 d.疗程结束后4 wk 复查内镜,观察 Hp 根治和溃疡愈合情况,并评价再生粘膜组织学成熟度.结果新三联和"灭 Hp 胶囊"四联组溃疡愈合率和 Hp 根治率分别为88%,92%和100%,96%,(P>0.05),但其再生粘膜成熟度后者(优占89%)优于前者(优占41%)(P<.05);两组均明显优于安慰剂组溃疡愈合率(20%,P<0.05),Hp 根治率(0.0%,均 P<0.01)和再生粘膜组织成熟度(以差者为主占67%,分别 P<0.05,P<0.01).结论灭 Hp 胶囊四联疗法不但获得理想的 Hp 根治率和溃疡愈合率,更有显著提高溃疡愈合质量作用;为中西医结合治疗消化性溃疡开辟了新途径.
文摘目的:探讨和总结陆金根教授治疗炎症性肠病的学术思想和临床用药规律,探索名老中医经验整理的方法。方法:收集上海中医药大学附属龙华医院2011—2017门诊陆金根教授治疗炎症性肠病典型医案,对所选医案中符合纳入标准的药物运用Excel表进行收录,然后用SPSS 21. 0 for windows统计软件进行聚类分析。结果:共有162份医案纳入研究,共计就诊622次,共得药物225味,出现的总频次为10411,常用中药有白术、败酱草、白芍、大血藤、山药等27味。聚类分析发现清热解毒药、化湿药、理气药、补虚药、收涩药和活血化瘀药等为陆金根教授治疗炎症性肠病的常用配伍药类。红藤败酱散、白头翁汤、痛泻要方、参苓白术散、甘麦大枣汤等为陆老治疗炎症性肠病的基本方药。结论:陆老治疗炎症性肠病体现出"以清为主,清补结合"的学术思想。聚类分析结果客观反映了陆金根教授临床用药规律。
